Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors

被引:8
|
作者
Zhou, Huaqiang [1 ,2 ]
Chen, Qinchang [2 ]
Tan, Wulin [1 ]
Qiu, Zeting [1 ,2 ]
Li, Si [2 ]
Song, Yiyan [2 ]
Gao, Shaowei [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anesthesia, 58 Zhongshan 2 Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Med, Guangzhou, Guangdong, Peoples R China
关键词
Pancreatic neuroendocrine tumors; mRNA; Protein-protein interaction network; CONJUGATING ENZYME UBCH10; CENTROSOMAL KINASE NEK2; ENDOCRINE TUMORS; ABNORMAL EXPRESSION; MOLECULAR SUBTYPES; TUMORIGENIC GROWTH; GLUCAGON RECEPTOR; BETA-CATENIN; LUNG-CANCER; USEFUL TOOL;
D O I
10.1016/j.gene.2017.05.009
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pancreatic neuroendocrine tumors are relatively rare pancreatic neoplasms over the world. Investigations about molecular biology of PNETs are insufficient for nowadays. We aimed to explore the expression of messenger RNA and regulatory processes underlying pancreatic neuroendocrine tumors from different views. The expression profile of GSE73338 were downloaded, including samples with pancreatic neuroendocrine tumors. First, the Limma package was utilized to distinguish the differentially expressed messenger RNA. Gene Ontology classification and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed to explore the functions and pathways of target genes. In addition, we constructed a protein-protein interaction network. NEK2, UBE2C, TOP2A and PPP1R1A were revealed with continuous genomic alterations in higher tumor stage. 91 up-regulated and 36 down-regulated genes were identified to be differentially expressed in malignant PNETs. Locomotory behavior was significantly enriched for biological processes of metastasis PNETs. GCGR and GNAS were identified as the hub of proteins in the protein-protein interaction sub-network of malignant PNETs. We showed the gene expression differences in PNETs according to different clinicopathological aspects. NEK2, UBE2C, TOP2A are positively associated with high tumor grade, and PPP1R1A negatively. GCGR and GNAS are regarded as the hub of the PPI sub-network. CXCR4 may affect the progression of PNETs via the CXCR4-CXCL12-CXCR7 chemokine receptor axis. However, more studies are required.
引用
收藏
页码:72 / 77
页数:6
相关论文
共 50 条
  • [41] Genomic landscape of pancreatic neuroendocrine tumors
    Niklas Gebauer
    Christian Schmidt-Werthern
    Veronica Bernard
    Alfred C Feller
    Tobias Keck
    Nehara Begum
    Dirk Rades
    Hendrik Lehnert
    Georg Brabant
    Christoph Thorns
    World Journal of Gastroenterology, 2014, 20 (46) : 17498 - 17506
  • [42] Pancreatic neuroendocrine tumors: A comprehensive review
    Zhou, Chenfei
    Zhang, Jun
    Zheng, Ying
    Zhu, Zhenggang
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : 1013 - 1022
  • [43] Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling
    Carr, Jennifer C.
    Boese, Erin A.
    Spanheimer, Philip M.
    Dandaleh, Fadi S.
    Martin, Molly
    Galva, Daniel
    Schafer, Blanca
    Thole, David M.
    Braun, Terry
    O'Dorisio, Thomas M.
    O'Dorisio, M. Sue
    Howe, James R.
    SURGERY, 2012, 152 (06) : 998 - 1007
  • [44] Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine Tumors Clinicopathological Analysis of 223 Cases and Whole Exome Sequencing of a Multifocal Case
    Hu, Hai-Feng
    Hu, Yu-Heng
    Xu, Xiao-Wu
    Ye, Zeng
    Lou, Xin
    Zhang, Wu-Hu
    Chen, Xue-Min
    Zhang, Yue
    Yu, Xian-Jun
    Gao, He-Li
    Xu, Jun-Yan
    Ji, Shun-Rong
    PANCREAS, 2022, 51 (10) : 1404 - 1410
  • [45] Clinical pathways for pancreatic neuroendocrine tumors
    Alistar A.
    Sung M.
    Kim M.
    Holcombe R.F.
    Journal of Gastrointestinal Cancer, 2012, 43 (4) : 532 - 540
  • [46] Multimodality Imaging of the Pancreatic Neuroendocrine Tumors
    Singh, Amandeep
    Hines, John J.
    Friedman, Barak
    SEMINARS IN ULTRASOUND CT AND MRI, 2019, 40 (06) : 469 - 482
  • [47] Everolimus for the treatment of pancreatic neuroendocrine tumors
    Feldmann, Georg
    Bisht, Savita
    Schuette, Ute
    Haarmann, Jens
    Brossart, Peter
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (14) : 2073 - 2084
  • [48] Pancreatic neuroendocrine tumors: Our approach
    Jagad, Rajan B.
    Koshariya, Mahim
    Kawamoto, Jun
    Papastratis, P.
    Kefalourous, H.
    Patris, V.
    Porfiris, T.
    Gevrielidis, Pascailis
    Tzouma, Christina
    Lygidakis, N. J.
    HEPATO-GASTROENTEROLOGY, 2008, 55 (81) : 275 - 281
  • [49] MR Imaging of Pancreatic Neuroendocrine Tumors
    Lo, Grace C.
    Kambadakone, Avinash
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2018, 26 (03) : 391 - +
  • [50] Surgical Management of Pancreatic Neuroendocrine Tumors
    Sulciner, Megan L.
    Clancy, Thomas E.
    CANCERS, 2023, 15 (07)